RxDoctor Payments Data

Abundio Castillo

Family · Taft, CANPI 1053888743

Payments from drug & device makers

$447in general payments, 2019–2025

Across 27 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$137
  • Exact Sciences$50
  • GSK$47
  • AstraZeneca$45
  • Boehringer Ingelheim$41
  • Medtronic$24
  • plus $104 from 6 others

What the payments were for

  • Food & beverage$447100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$447 in reported general payments places this provider in the 55th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$3,879
Medicare patients
69
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$118,332
OzempicSemaglutide65$65,130
FarxigaDapagliflozin Propanediol51$57,147
BiktarvyBictegrav/Emtricit/Tenofov Ala11$49,928
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,656
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$9,255
SynjardyEmpagliflozin/Metformin Hcl11$5,632
Albuterol Sulfate HfaAlbuterol Sulfate102$2,711
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,335
Rosuvastatin Calcium40$1,042
Pregabalin35$1,037
Tamsulosin Hcl40$846
ConstuloseLactulose26$747
Lactulose34$736
Fluconazole23$717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$41$123,964102 claims
AstraZenecaFarxiga, Breztri Aerosphere$45$67,80367 claims
Novo NordiskOzempic$18$65,13065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,634 family providers in California.

Other family in Taft

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →